 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
7 News |  |
- zaltenibart (OMS906) / Omeros
Population Pharmacokinetics/Pharmacodynamics and Clinical Pharmacology of Zaltenibart (OMS906) in Healthy Subjects and Patients with PNH (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_3580;
The latter is directly observed to protect against both intravascular and extravascular hemolysis in PNH pts. Taken together, these data sources will enable threshold concentrations to be identified and applied to dose/dose regimen simulations to identify the optimal dose providing durable control of hemolysis in pts with PNH.
- zaltenibart (OMS906) / Omeros
Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_3571;
P1b
Zaltenibart monotherapy resulted in sustained clinically meaningful improvements in Hb and ARC and prevented both IVH and EVH. Data from this interim analysis support the potential for zaltenibart as monotherapy for treating PNH in pts with suboptimal response to C5 inhibitors.
- || zaltenibart (OMS906) / Omeros
Enrollment open, Trial completion date: Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN (clinicaltrials.gov) - Apr 18, 2024
P2, N=20, Recruiting, Sponsor: Omeros Corporation
Data from this interim analysis support the potential for zaltenibart as monotherapy for treating PNH in pts with suboptimal response to C5 inhibitors. Not yet recruiting --> Recruiting | Trial completion date: Jun 2025 --> Apr 2026
- || zaltenibart (OMS906) / Omeros
New P2 trial: Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria (clinicaltrials.gov) - Mar 6, 2024
P2, N=25, Recruiting, Sponsor: Omeros Corporation
- || zaltenibart (OMS906) / Omeros
New P2 trial: Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN (clinicaltrials.gov) - Jan 17, 2024
P2, N=20, Not yet recruiting, Sponsor: Omeros Corporation
- OMS906 / Omeros
Alternative Pathway Masp-3 Inhibitor OMS906 Effectively and Potently Inhibits Complement-Mediated Hemolysis in Preclinical Models Mechanistically Similar to Paroxysmal Nocturnal Hemoglobinur... (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_5507;
In addition, OMS906 improved survival of Crry -/- RBCs comparably to a CFB inhibitor, indicating that MASP-3 inhibition prevents the AP-mediated destruction of RBCs predictive of extravascular hemolysis. OMS906 is currently in clinical development for the treatment of PNH.
- OMS906 / Omeros
OMS906, a Novel Alternative Pathway MASP-3 Inhibitor, Normalizes Hemoglobin Levels and Increases Clone Size in Treatment-Na (SDCC - Room 7) - Nov 3, 2023 - Abstract #ASH2023ASH_3248;
P1b
In this interim analysis, MASP-3 inhibitor OMS906 was well tolerated with no safety signals of concern. Once-monthly SC OMS906 resulted in clinically meaningful, beneficial effects on Hgb, LDH, and RBC clone size in treatment-na
- || zaltenibart (OMS906) / Omeros
New P1 trial: Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab (clinicaltrials.gov) - Aug 2, 2023
P1b, N=12, Recruiting, Sponsor: Omeros Corporation
- ||||| OMS906 / Omeros
Clinical, P1 data: Very proud to listen to Jens Panse of @UniklinikAachen @RWTH presenting the phase 1 data of the MASP-3 inhibitor OMS906 in patients with #PNH at #EHA2023 ! Great job, Jens ! #cioabcd (Twitter) - Jun 10, 2023
- || zaltenibart (OMS906) / Omeros
New P1 trial: OMS906-PNH-002: Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria (clinicaltrials.gov) - Jun 5, 2023
P1b, N=10, Recruiting, Sponsor: Omeros Corporation
- OMS906 / Omeros
OMS906, A MANNAN-BINDING LECTIN-ASSOCIATED SERINE PROTEASE-3 (MASP-3) INHIBITOR, NORMALIZES HEMOGLOBIN LEVELS IN TREATMENT-NA (festival hall) - Jun 1, 2023 - Abstract #EHA2023EHA_3620;
Once-monthly SC OMS906 resulted in clinically meaningful, beneficial effects on Hgb, LDH, and RBC clone size in treatment-na In this interim analysis of a proof-of-concept study of MASP-3 inhibition, once-monthly SC OMS906 in treatment-na
- OMS906 / Omeros
ALTERNATIVE PATHWAY MASP-3 INHIBITOR OMS906: RESULTS FROM A FIRST-IN-MAN PHASE 1 STUDY IN HEALTHY SUBJECTS AND STUDY DESIGN OF TWO ONGOING CLINICAL TRIALS IN PATIENTS WITH PNH (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1029;
In this interim analysis of a proof-of-concept study of MASP-3 inhibition, once-monthly SC OMS906 in treatment-na The first is enrolling patients with a sub-optimal response to ravulizumab treatment; the second is enrolling treatment-na
- OMS906 / Omeros
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Alternative Pathway Masp-3 Inhibitor OMS906 in a Phase 1 Study of Healthy Subjects (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_3992;
There were no serious AEs. The most common AEs were ISRs, predominantly observed in the SC OMS906 cohorts.
- || OMS906 / Omeros
#OMS906? #MASH3 @OmerosCorp (Twitter) - May 13, 2021
- || OMS906 / Omeros
IND: Omeros’ Investigational New Drug Application for OMS906 Cleared by FDA https://t.co/em8kADwTvT (Twitter) - Aug 31, 2020